Advertisement
Home Blog Page 3111
Lixisenatide is more effective than placebo for older patients with uncontrolled diabetes on their current medication

Lixisenatide Beneficial in Seniors With Uncontrolled Diabetes

0
Improved HbA1c reduction versus placebo in older patients uncontrolled on current medications
The risks of adverse events are similar with short-term use of typical and atypical antipsychotic medications after cardiac surgery in seniors

Similar Adverse Event Risk for Typical, Atypical Antipsychotics

0
However, greater use of brain imaging associated with atypical APMs after cardiac surgery in seniors
Health care utilization is common after appropriate and inappropriate implantable cardioverter-defibrillator shock events

Health Care Utilization Common After ICD Shock Events

0
Forty-six percent of shock events have related health care use, with cardiac catheterization common
Among children with non-alcoholic fatty liver disease

Uric Acid Concentration, Fructose Intake Up NASH in Children

0
Independent associations seen in cohort of obese children with non-alcoholic fatty liver disease
For severely obese patients

Bariatric Embolization Feasible for Severely Obese

0
Technical success rate of 100 percent in five patients, with no major adverse events observed
For patients with type 2 diabetes mellitus

Dulaglutide Linked to Higher Adherence in T2DM

0
Higher adherence, lower discontinuation versus exenatide once weekly or liraglutide
Close to 300 genetic regions tied to male pattern baldness have been identified

Nearly 300 Genetic Regions Linked to Male Pattern Baldness

0
Findings could provide targets for treatment
Cardiovascular disease is increasing in the United States

AHA: CVD Expected to Cost U.S. $1.1 Trillion Per Year by 2035

0
American Heart Association estimates CVD-related disease in nearly half of Americans in <20 years
Scalp cooling devices may reduce chemotherapy-induced alopecia in patients with breast cancer

Scalp Cooling Device May Help Reduce Chemo-Induced Alopecia

0
Findings in women receiving chemotherapy for breast cancer
For patients with Barrett's esophagus

No Chemopreventive Effect Seen for H2RAs in Barrett’s Esophagus

0
PPI use, but not H2 receptor antagonists, linked to reduced risk of progression in Barrett's esophagus